When was Engage Bio founded?

Engage Bio was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Engage Bio located?

Engage Bio is headquartered in Santa Clara, United States.

How many employees does Engage Bio have?

As of Apr 30, 2026, the latest employee count at Engage Bio is 9.

Is Engage Bio a funded company?

Engage Bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Mar 29, 2022.

When was the latest funding round of Engage Bio?

Engage Bio's latest funding was a $***** Seed round on Mar 29, 2022, with participation from 1 investor.

Where does Engage Bio rank among its competitors?

Engage Bio ranks 909th amongst 2421 active competitors, of which 840 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Engage Bio?

Engage Bio's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Among them, Karyopharm secured the most recent funding round in March, 2026.

Engage Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of immunotherapies for the treatment of cancer. The company focuses on the development of mRNA drugs that act as immunotherapies and engage the immune system and redirect it to target cancer.

Website: engagebio.com
Email ID: *****@engagebio.com

Key Metrics

Founded Year

2021

Location

Santa Clara, United States

Stage

Seed

Total Funding

$500K in 1 round

Latest Funding Round

Seed, Mar 29, 2022, $*****

Investors

WorldQuant Ventures & 3 more

Ranked

909^th among 2421 active competitors

Employee Count

9 as on Apr 30, 2026

Similar Companies

Moderna & 24 more

View Engage Bio's full profile

Engage Bio has raised a total funding of $500K over 1 round. Its latest funding round was a Seed round on Mar 29, 2022 for $*****. 1 investor participated in its latest round. Engage Bio has 4 institutional investors.

Here is the list of recent funding rounds of Engage Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 29, 2022	5922670	Seed	6931331	4141964	8408425	5142564

Access funding benchmarks and valuations. Sign up today!

View details of Engage Bio's funding rounds and investors

The founders of Engage Bio are Will Olsen and Kathryn Strobel Kwant.

Here are the details of Engage Bio's key team members:

Will Olsen: Co-Founder of Engage Bio and founder of 2 other companies, Luminist and Luminist. They are also an angel investor in 1 startup.
Kathryn Strobel Kwant: Co-Founder and CSO of Engage Bio.

View details of Engage Bio's Founder profiles and Board Members

Engage Bio's employee count trend

Engage Bio has 9 employees as of Apr 26. Here is Engage Bio's employee count trend over the years:

Uncover Engage Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Engage Bio include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Here is the list of Top 10 competitors of Engage Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
3rd	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 18 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	71/100
9th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
909th	Engage Bio 2021, Santa Clara (United States), Seed	Developer of immunotherapies for the treatment of cancer	$500K	WorldQuant Ventures, Y Combinator & 2 others	38/100